Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study

Abstract Background Emerging evidence indicates that estrogen receptor-low (ER-low)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) may more closely resemble ER-negative (ER-zero, < 1%) rather than ER-positive disease in terms of biological and clinicopathological charac...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Sanna Steen, Emelie Karlsson, Ida Björnheden, Gunilla Rask, Viktoria Thurfjell, Hampus Nobin, Blanka Kolodziej, Anna Bodén, Annette Bauer, Rickard Einefors, Per Nilsson, Ioannis Zerdes, Andri Papakonstantinou, Theodoros Foukakis, Irma Fredriksson, Mattias Rantalainen, Eugenia Colón-Cervantes, Anikó Kovács, Balazs Acs, Johan Hartman
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	BMC 2025-11-01
श्रृंखला:	Breast Cancer Research
विषय:	Triple negative breast cancer Neoadjuvant immunotherapy Pembrolizumab ER low
ऑनलाइन पहुंच:	https://doi.org/10.1186/s13058-025-02179-3
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!